Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Cash Flow-to-Debt Ratio of -0.01x as of March 2026, meaning its operating cash flow of $-91.25K could theoretically repay 0% of its total liabilities ($7.39 Million) in one year. Check how aggressively does Drugs Made In America Acquisition Corp. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Ordinary Shares across 2 annual periods. Also explore Drugs Made In America Acquisition Corp. (DMAA) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Ordinary Shares. For market capitalisation and broader financial context, see Drugs Made In America Acquisition Corp. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $795.67 | — |